生物制药公司Erasca, Inc.(纳斯达克代码:ERAS)与Tango Therapeutics Inc.(纳斯达克代码:TNGX)宣布建立临床合作,将共同开展针对ERAS-0015与vopimetostat联合疗法的临床评估。该合作旨在探索两种创新疗法联用的潜力,为患者提供更有效的治疗选择。
双方计划通过临床研究验证联合方案的协同效应,重点关注其在特定适应症中的安全性与疗效。这一合作标志着两家公司在肿瘤治疗领域迈出的重要一步,有望加速创新疗法的开发进程。
生物制药公司Erasca, Inc.(纳斯达克代码:ERAS)与Tango Therapeutics Inc.(纳斯达克代码:TNGX)宣布建立临床合作,将共同开展针对ERAS-0015与vopimetostat联合疗法的临床评估。该合作旨在探索两种创新疗法联用的潜力,为患者提供更有效的治疗选择。
双方计划通过临床研究验证联合方案的协同效应,重点关注其在特定适应症中的安全性与疗效。这一合作标志着两家公司在肿瘤治疗领域迈出的重要一步,有望加速创新疗法的开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.